热门资讯> 正文
周五报道称，Neurosrine Biosciences的CRENENSITY获得FDA批准，彻底改变了经典先天性肾上腺增生症的治疗方法
2024-12-16 15:30
- CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach
- FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAHCRENESSITY is expected to be commercially available in approximately one week
Rare Pediatric Disease Priority Review Voucher granted in connection with approval
- FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAHCRENESSITY is expected to be commercially available in approximately one week
推荐文章
美股机会日报 | 8月非农大幅低于预期！纳指期货短线拉涨约0.7%；特斯拉盘前涨近2%
一周财经日历 | 事关降息！中美5月CPI、PPI重磅出炉！新股“超购王”大行科工下周上市
高盛：降新鸿基地产目标价至96港元 评级“买入”
特朗普白宫宴请硅谷巨头 各大公司CEO纷纷重申在美投资承诺
非农前糟糕就业数据引爆降息预期 10年期美债收益率创四个月新低
AI收入超预期！芯片巨头博通交出满分财报 神秘百亿订单带来惊喜
Lululemon Athletica连续第二次下调全年业绩指引 盘后股价一度暴跌超15%
9月5日外盘头条：马斯克回绝白宫科技CEO晚宴邀请 波音罢工持续无奈招募替代工人 露露柠檬股价盘后暴跌10%
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
